Veracyte, Inc. $VCYT Stock: Sumitomo Mitsui Trust Group Inc. Boosts Holdings

Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Veracyte, Inc. (NASDAQ:VCYT) by 2.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 784,483 shares of the biotechnology company’s stock after purchasing an additional 15,534 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Veracyte were worth $36,118,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Veracyte during the second quarter valued at approximately $792,058,000. Dimensional Fund Advisors LP increased its position in shares of Veracyte by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,881,090 shares of the biotechnology company’s stock worth $92,787,000 after purchasing an additional 80,614 shares in the last quarter. First Trust Advisors LP increased its position in shares of Veracyte by 64.9% during the first quarter. First Trust Advisors LP now owns 2,117,046 shares of the biotechnology company’s stock worth $68,190,000 after purchasing an additional 833,543 shares in the last quarter. Congress Asset Management Co. acquired a new position in Veracyte in the 3rd quarter valued at $89,971,000. Finally, Bank of America Corp DE raised its stake in Veracyte by 14.7% in the 1st quarter. Bank of America Corp DE now owns 1,448,897 shares of the biotechnology company’s stock valued at $46,669,000 after purchasing an additional 185,929 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on VCYT. Wall Street Zen downgraded shares of Veracyte from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Canaccord Genuity Group dropped their price objective on shares of Veracyte from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. Morgan Stanley cut their price objective on shares of Veracyte from $47.00 to $44.00 and set an “underweight” rating for the company in a report on Tuesday, August 4th. Needham & Company LLC reissued a “buy” rating on shares of Veracyte in a research note on Tuesday, September 15th. Finally, UBS Group lifted their price objective on Veracyte from $52.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Veracyte has a consensus rating of “Moderate Buy” and a consensus target price of $55.78.

Veracyte News Summary

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Third-quarter revenue rose 15% year over year to $151.8 million, beating the $147.1 million consensus estimate. Adjusted EPS of $0.51 also topped estimates of $0.41–$0.44, though it was unchanged from a year earlier. Veracyte Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The company authorized a $100 million share repurchase program. Buybacks can signal management confidence and support per-share results by reducing the number of shares outstanding. Veracyte authorizes a Buyback Plan
• Neutral Sentiment: Analysts’ average price target was reported at $55.78. The target suggests some potential upside from the $52.52 opening price cited in the background, but it is an estimate rather than a guarantee. Veracyte Stock Has Average Price Target of $55.78

Insiders Place Their Bets

In other Veracyte news, insider John Leite sold 4,015 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $40.00, for a total value of $160,600.00. Following the transaction, the insider directly owned 124,329 shares of the company’s stock, valued at $4,973,160. This represents a 3.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Phillip Febbo sold 13,110 shares of Veracyte stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $43.05, for a total value of $564,385.50. Following the completion of the transaction, the insider owned 133,048 shares of the company’s stock, valued at approximately $5,727,716.40. The trade was a 8.97% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 62,609 shares of company stock valued at $2,858,904. Insiders own 1.60% of the company’s stock.

Veracyte Stock Performance

VCYT opened at $52.52 on Thursday. The stock has a market capitalization of $4.22 billion, a P/E ratio of 37.25 and a beta of 1.98. Veracyte, Inc. has a one year low of $29.45 and a one year high of $60.91. The business’s 50-day simple moving average is $44.90 and its 200-day simple moving average is $43.04.

Veracyte (NASDAQ:VCYT) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.10. The company had revenue of $151.75 million during the quarter, compared to the consensus estimate of $147.13 million. Veracyte had a return on equity of 9.26% and a net margin of 20.37%. Veracyte’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.51 earnings per share. On average, equities research analysts forecast that Veracyte, Inc. will post 1.32 EPS for the current fiscal year.

About Veracyte

Veracyte, Inc is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests are designed to provide additional molecular information from patient samples, often helping reduce uncertainty and support more personalized care.

The company’s portfolio includes Afirma tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests for breast cancer. Veracyte also develops and commercializes additional genomic assays intended for use across various cancer types and clinical settings.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte primarily serves the U.S.